Halia Therapeutics, Inc.

Halia Therapeutics is a clinical-stage biopharmaceutical company headquartered in Lehi, Utah. Founded in 2017, Halia focuses on developing innovative therapies for a wide range of chronic inflammatory disorders and neurodegenerative diseases, including Alzheimer's, Parkinson's, rheumatoid arthritis, obesity, and cancer. They are pioneering the use of small molecule medications that target the NLRP3 inflammasome, a large protein complex that plays a key role in the body's inflammatory response. Halia's lead candidate, HT-6184, is a NEK7 inhibitor, designed to block the interaction of NEK7 and NLRP3, preventing the formation of the inflammasome.

Halia's mission is to improve patient lives by disrupting chronic inflammation. They are committed to advancing a pipeline of therapeutics that are designed to reduce inflammation and reset the inflammatory pathway. The company is currently in the early stages of clinical trials to test the safety and efficacy of this approach in patients. Halia's research is based on a groundbreaking scientific discovery by their co-founder, Dr. John "Keoni" Kauwe, who identified a family with a genetic risk for Alzheimer's disease but none of whom developed the illness. He found a protective gene mutation that also blocked inflammation, leading Halia to explore the potential of tackling inflammation as a key to treating a wide range of diseases.

Halia Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies that improve the lives of patients worldwide by targeting chronic inflammation. Recognizing the link between inflammation and numerous chronic diseases, including Alzheimer's, cardiovascular disease, cancer, and various disorders of the skin, intestines, and liver, Halia is pioneering a method to disrupt chronic inflammation through a specific inflammatory pathway.

Halia Therapeutics promotes a culture focused on innovation, collaboration, and a dedication to improving patient lives. They value scientific excellence and integrity, fostering a collaborative environment where employees can contribute their unique expertise and talents. Their commitment to research and development is evident in their numerous clinical trials and partnerships with other organizations. This results in a dynamic and fast-paced environment where employees are encouraged to push boundaries and contribute to the development of transformative therapies.